Tuesday October 9, 2012 0 commentsFORT COLLINS - Ventria Bioscience announced that its Optiferrin product has been shown to be biochemically and structurally similar to human transferrin molecules derived from human serum or a recombinant mammalian expression system, according to a paper published in the Journal of Inorganic Biochemistry.
Optiferrin is sold commercially by InVitria, the bioreagents division of Ventria Bioscience, for use in cell culture applications.
The paper, titled "Biochemical and Structural Characterization of Recombinant Human Serum Transferrin from Rice," was the result of a collaboration between researchers at the University of Vermont College of Medicine's Department of Biochemistry, the University of Massachusetts at Amherst's Department of Chemistry, Ventria Bioscience and InVitria.
Human transferrin, either purified from human blood serum or biomanufactured using various recombinant protein expression systems, is widely used in biomedical research and the biotechnology industry as a supplement to support mammalian cell growth in serum-free culture media.
It also has potential therapeutic uses in the treatment of thalassemia, atransferrinemia and age-related macular degeneration, and as an anti-cancer drug delivery molecule.
"While we have long known that Optiferrin supports optimal cell growth in serum-free media, this study provides further validation that recombinant human transferrin produced using our Express Tec technology functions similarly to its endogenuous counterpart," said Scott Deeter, Ventria's president and CEO.
"These results will support our future efforts toward developing a cost-effective, biopharmaceutical-grade human transferrin product."
For more information, visit www.ventria.com